Compare Stocks → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALDXNASDAQ:IFRXNASDAQ:LUMONASDAQ:MBIONASDAQ:PHAS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$3.95+1.0%$3.61$1.42▼$11.97$232.66M1.51580,572 shs179,507 shsIFRXInflaRx$1.33-2.2%$1.55$1.14▼$5.20$78.31M1.27238,364 shs47,042 shsLUMOLumos Pharma$2.72-2.9%$2.84$2.41▼$4.55$22.09M0.6520,698 shs38,309 shsMBIOMustang Bio$0.34-5.5%$0.98$0.33▼$8.17$3.53M1.58176,533 shs34,572 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shsN/ABeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-0.51%+1.03%+34.83%+30.33%-58.62%IFRXInflaRx-0.73%+3.82%-8.72%-15.00%-71.43%LUMOLumos Pharma+4.48%+11.11%+0.72%+0.36%-12.23%MBIOMustang Bio+5.79%-1.72%-66.69%-73.74%-91.46%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%-76.19%The system that called 2023’s top 7 stocks is at it again… (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALDXAldeyra Therapeutics2.2222 of 5 stars3.53.00.00.02.52.50.0IFRXInflaRx2.1871 of 5 stars3.83.00.00.00.01.71.3LUMOLumos Pharma1.5177 of 5 stars3.51.00.00.00.02.51.3MBIOMustang Bio2.0286 of 5 stars3.55.00.00.02.40.00.0PHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics3.00Buy$9.33136.29% UpsideIFRXInflaRx3.50Strong Buy$13.50915.04% UpsideLUMOLumos Pharma3.00Buy$18.00561.76% UpsideMBIOMustang Bio3.00Buy$17.254,973.53% UpsidePHASPhaseBio PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest ALDX, IFRX, PHAS, LUMO, and MBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2024ALDXAldeyra TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$10.004/2/2024ALDXAldeyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/22/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/20/2024LUMOLumos PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.001/25/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$2.04 per shareN/AIFRXInflaRx$70K1,118.72N/AN/A$1.89 per share0.70LUMOLumos Pharma$2.05M10.77N/AN/A$3.45 per share0.79MBIOMustang BioN/AN/AN/AN/A$0.01 per shareN/APHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$37.54M-$0.64N/AN/AN/AN/A-29.45%-24.24%5/2/2024 (Estimated)IFRXInflaRx-$46.18M-$0.86N/AN/AN/AN/A-40.10%-36.24%5/9/2024 (Estimated)LUMOLumos Pharma-$34.03M-$4.19N/AN/AN/A-1,659.39%-85.63%-65.30%5/1/2024 (Estimated)MBIOMustang Bio-$51.60M-$6.00N/A∞N/AN/A-433.08%-146.39%5/10/2024 (Estimated)PHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ALatest ALDX, IFRX, PHAS, LUMO, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023IFRXInflaRx-$0.20-$0.30-$0.10-$0.30N/AN/A3/11/2024Q4 2023MBIOMustang Bio-$1.68-$0.71+$0.97-$0.71N/AN/A3/7/2024Q4 2023ALDXAldeyra Therapeutics-$0.21-$0.08+$0.13-$0.08N/AN/A3/7/2024Q4 2023LUMOLumos Pharma-$1.18-$1.17+$0.01-$1.17$0.01 million$0.83 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/ALUMOLumos PharmaN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A6.646.64IFRXInflaRxN/A6.505.82LUMOLumos PharmaN/A5.695.69MBIOMustang BioN/A0.740.74PHASPhaseBio PharmaceuticalsN/A0.470.47OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%IFRXInflaRx42.39%LUMOLumos Pharma33.99%MBIOMustang Bio9.95%PHASPhaseBio Pharmaceuticals49.02%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics7.30%IFRXInflaRx16.30%LUMOLumos Pharma25.40%MBIOMustang Bio2.10%PHASPhaseBio Pharmaceuticals9.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1558.90 million54.60 millionOptionableIFRXInflaRx6258.88 million49.29 millionOptionableLUMOLumos Pharma338.12 million6.06 millionNot OptionableMBIOMustang Bio8010.39 million10.17 millionNot OptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableALDX, IFRX, PHAS, LUMO, and MBIO HeadlinesSourceHeadlineModified Release Neurology Therapeutics Report 202…pharmiweb.com - February 19 at 2:09 PMVelia Therapeutics Appoints Michael York as Chief Business Officerfinance.yahoo.com - December 14 at 8:55 AMLeading innovators in GLP-1 analogues for the pharmaceutical industrypharmaceutical-technology.com - November 6 at 7:00 AMAlcami Announces CEO Transitionfinance.yahoo.com - June 5 at 10:33 AM8-K: PhaseBio Pharmaceuticals Incmarketwatch.com - May 12 at 2:46 AMAbsci Corporation: Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Resultsfinanznachrichten.de - March 31 at 6:59 PMBioCryst Pharmaceuticals, Inc.: BioCryst Appoints Dr. Nancy Hutson as Chair of the Boardfinanznachrichten.de - March 31 at 1:59 PMBioCryst Appoints Dr. Nancy Hutson as Chair of the Boardfinance.yahoo.com - March 31 at 8:59 AMCardiomyopathy Medication Market Size and Forecast till 2031marketwatch.com - March 22 at 1:16 PMCardiomyopathy Medication Market Emerging Demand and Drive Growth by 2028 with Top Countries Datamarketwatch.com - February 28 at 1:24 PMJi Xing obtains global rights to cardiovascular candidate from Phasebiobioworld.com - February 9 at 7:59 AMBankrupt PhaseBio settles with investor-partner, handing off late-stage drugendpts.com - January 18 at 11:29 PMSFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio Pharmaceuticalsbenzinga.com - January 17 at 12:24 PMBankruptcy court approves PhaseBio's $32.9M asset transfer dealbizjournals.com - January 5 at 7:47 PMBankrupt PhaseBio Identifies Chiesi as Lead Bidder for Bentracimab Assetsmarketwatch.com - November 8 at 12:22 AMShort Volatility Alert: PhaseBio Pharmaceuticals, Inc.benzinga.com - November 4 at 2:57 PMWhy Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Sessionmsn.com - November 2 at 6:43 PMWhy Goodyear Tire & Rubber Shares Are Trading Lower; Here Are 24 Stocks Moving Premarketmsn.com - November 1 at 12:30 PMPhaseBio Pharmaceuticals 10% Owner Trades Company's Stockbenzinga.com - October 27 at 4:54 PMPhaseBio Files for Bankruptcy Following Blackstone-Backed Partner’s Lawsuitwsj.com - October 25 at 5:37 AMPhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $100Mbizjournals.com - October 25 at 5:37 AMPhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code (Businesswire)avanza.se - October 24 at 12:07 PMAs top investor makes its play to grab lead drug, PhaseBio counters with Chapter 11, stalking-horse bidendpts.com - October 24 at 12:07 PMPhaseBio Pharma Files For Chapter 11 Bankruptcy Protectionnasdaq.com - October 24 at 12:07 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? April 9, 2024 6:07 AMView Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? Penny Stock Quantum-Si Incorporated Readies For Lift-OffApril 9, 2024 7:14 AMView Penny Stock Quantum-Si Incorporated Readies For Lift-OffAll Headlines Company DescriptionsAldeyra TherapeuticsNASDAQ:ALDXAldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.InflaRxNASDAQ:IFRXInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Lumos PharmaNASDAQ:LUMOLumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.Mustang BioNASDAQ:MBIOMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.PhaseBio PharmaceuticalsNASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.